Published in Neurology on September 28, 2004
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Reversible central neurogenic hyperventilation in an awake patient with multiple sclerosis. J Neurol (2007) 1.39
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Vision and vision-related outcome measures in multiple sclerosis. Brain (2014) 1.08
Optic neuritis. Eye (Lond) (2011) 1.05
Neuromyelitis Optica. Curr Treat Options Neurol (2005) 0.93
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91
Optic neuritis in neuromyelitis optica. Prog Retin Eye Res (2013) 0.90
Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int (2012) 0.90
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation (2012) 0.88
Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry (2014) 0.86
Corticosteroids and plasma exchange in multiple sclerosis. J Neurol (2008) 0.85
Management of acute exacerbations in multiple sclerosis. Ann Indian Acad Neurol (2009) 0.85
Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. PLoS One (2015) 0.84
Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange. J Neurol (2007) 0.80
Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J Neurol (2007) 0.80
Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.80
Multiple sclerosis therapy: an update on recently finished trials. J Neurol (2007) 0.78
Baseline magnetic resonance imaging of the optic nerve provides limited predictive information on short-term recovery after acute optic neuritis. PLoS One (2015) 0.78
Plasmapheresis: are bigger studies necessarily better? Nat Rev Neurol (2012) 0.75
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study. J Res Med Sci (2012) 0.75
Plasma exchange for steroid unresponsive Devic's disease. Indian J Nephrol (2012) 0.75
Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach. J Neurol (2006) 0.75
Optic neuritis as an early sign of multiple sclerosis. Eye Brain (2016) 0.75
Plasma exchange response in 34 patients with severe optic neuritis. J Neurol (2016) 0.75
[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis]. Nervenarzt (2007) 0.75
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol (1995) 2.34
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Impact of multiple sclerosis relapses on progression diminishes with time. Neurology (2009) 1.86
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med (1990) 1.60
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol (2000) 1.55
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.40
Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology (1999) 1.39
Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol (1991) 1.38
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol (1974) 1.34
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol (1989) 1.31
A specific circulating antigen in hamsters infected with Schistosoma mansoni. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. Am J Trop Med Hyg (1969) 1.30
Induction of nuclear factor-kappa B and the human immunodeficiency virus long terminal repeat by okadaic acid, a specific inhibitor of phosphatases 1 and 2A. New Biol (1990) 1.28
The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med (1990) 1.27
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer (1999) 1.20
Adenoviral pneumonia and its complications in infancy and childhood. J Can Assoc Radiol (1969) 1.20
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol (2005) 1.20
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology (2007) 1.20
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods (1997) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Diffusion of ions in myelinated nerve fibers. Biophys J (1979) 1.14
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis (1977) 1.13
Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA (1990) 1.12
Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J (1989) 1.12
Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett (1996) 1.11
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr (1982) 1.09
[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]. Nervenarzt (2001) 1.08
Analysis of the mouse gamma-crystallin gene family: assignment of multiple cDNAs to discrete genomic sequences and characterization of a representative gene. Nucleic Acids Res (1984) 1.08
Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med (1995) 1.08
Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol (2006) 1.08
Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. AJNR Am J Neuroradiol (2010) 1.08
Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging (2003) 1.07
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ (1997) 1.06
Influenza vaccination of high-risk children: a survey of three physician groups. Can J Public Health (1999) 1.06
Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol (1997) 1.06
Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis. Int MS J (2009) 1.06
A symposium: Should homosexuality be in the APA nomenclature? Am J Psychiatry (1973) 1.06
Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol (1993) 1.05
Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand (2008) 1.04
Arthritis associated with Haemophilus influenzae meningitis: septic or reactive? J Pediatr (1986) 1.04
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol (2007) 1.04
Meningococcal meningitis in familial deficiency of the fifth component of complement. Pediatrics (1981) 1.03
Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci (2000) 1.03
Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr (1987) 1.03
Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther (1984) 1.03
Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain (2001) 1.02
["Fatigue" in multiple sclerosis. Development and and validation of the "Würzburger Fatigue Inventory for MS"]. Nervenarzt (2006) 1.02
Painful vascular compression syndrome of the sciatic nerve caused by gluteal varicosities. Neurology (2003) 1.01
Orthostatic tremor in three brothers. J Neurol (2007) 1.01
Emerging oral therapies for multiple sclerosis. Int J Clin Pract (2007) 1.00
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology (2010) 1.00